[Efficacy and perspectives of use of vasaprostan (prostaglandin E1) in rheumatology].
Gusev
N G
NG
D000527:Alprostadil / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D000527:Alprostadil